ZA201906832B - Novel psma-binding agents and uses thereof - Google Patents
Novel psma-binding agents and uses thereofInfo
- Publication number
- ZA201906832B ZA201906832B ZA2019/06832A ZA201906832A ZA201906832B ZA 201906832 B ZA201906832 B ZA 201906832B ZA 2019/06832 A ZA2019/06832 A ZA 2019/06832A ZA 201906832 A ZA201906832 A ZA 201906832A ZA 201906832 B ZA201906832 B ZA 201906832B
- Authority
- ZA
- South Africa
- Prior art keywords
- binding agents
- novel psma
- psma
- novel
- radiopharmaceuticals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
- A61B6/5229—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image
- A61B6/5235—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image combining images from the same or different ionising radiation imaging techniques, e.g. PET and CT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- High Energy & Nuclear Physics (AREA)
- Surgery (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17000891 | 2017-05-24 | ||
| PCT/EP2017/000717 WO2018233798A1 (en) | 2017-06-20 | 2017-06-20 | NOVEL PSMA BINDING AGENTS AND USE THEREOF |
| PCT/EP2018/063734 WO2018215627A1 (en) | 2017-05-24 | 2018-05-24 | Novel psma-binding agents and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201906832B true ZA201906832B (en) | 2024-02-28 |
Family
ID=62200468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/06832A ZA201906832B (en) | 2017-05-24 | 2019-10-16 | Novel psma-binding agents and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11629201B2 (enExample) |
| EP (1) | EP3630204B1 (enExample) |
| JP (1) | JP7340459B2 (enExample) |
| KR (1) | KR102843240B1 (enExample) |
| CN (1) | CN110740757B (enExample) |
| AU (1) | AU2018274184B2 (enExample) |
| CA (1) | CA3060143A1 (enExample) |
| WO (1) | WO2018215627A1 (enExample) |
| ZA (1) | ZA201906832B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018352731B2 (en) * | 2017-10-22 | 2023-10-05 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| EP3887795A1 (en) * | 2018-11-30 | 2021-10-06 | Perkinelmer Health Sciences Inc. | Biological sample preparation using electric fields |
| CA3127188A1 (en) * | 2019-01-17 | 2020-07-23 | Case Western Reserve University | Peptide pet/spect probes specific to oncoproteins in tumor extracellularmatrix |
| CA3136979A1 (en) | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer |
| EP3976025A4 (en) * | 2019-05-24 | 2023-05-17 | Clarity Pharmaceuticals Limited | PSMA IMAGING AGENT FORMULATIONS |
| WO2020252598A1 (en) | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| TWI803688B (zh) * | 2019-08-26 | 2023-06-01 | 行政院原子能委員會核能研究所 | 一種psma靶向放射診療藥物備製方法 |
| KR102269315B1 (ko) * | 2019-10-24 | 2021-06-24 | 서울대학교산학협력단 | 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물 |
| CN113350531A (zh) * | 2020-03-02 | 2021-09-07 | 上海核力星医药科技有限公司 | 前列腺特异性膜抗原结合配体偶联物及其应用 |
| WO2022096103A1 (en) | 2020-11-05 | 2022-05-12 | ITM Isotopen Technologien München AG | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
| EP4244216A1 (en) * | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| WO2022111800A1 (en) | 2020-11-25 | 2022-06-02 | Itm Solucin Gmbh | Stable formulations for radionuclide complexes |
| US20240174622A1 (en) * | 2021-03-04 | 2024-05-30 | Nihon Medi-Physics Co., Ltd. | Compound and radioactive labeling compound |
| CN116940557A (zh) * | 2021-03-04 | 2023-10-24 | 日本医事物理股份有限公司 | 化合物及放射性标记化合物 |
| EP4341296A4 (en) * | 2021-05-21 | 2025-07-30 | Northstar Medical Tech Llc | RADIOPHARMACEUTICAL PRODUCT TARGETING THE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR |
| JP2024532521A (ja) | 2021-09-03 | 2024-09-05 | 晶核生物医藥科技（南京）有限公司 | ペプチド－尿素誘導体、それを含む医薬組成物、及びそれらの使用 |
| CN115806529A (zh) * | 2021-09-15 | 2023-03-17 | 威智医药有限公司 | Psma结合剂及其用途 |
| US20250222143A1 (en) * | 2021-10-20 | 2025-07-10 | The Research Foundation For The State University Of New York | Targeted radiotheranostics based on polyazamacrocyclic, mixed-donor scaffolds linked to a targeting vector |
| WO2023083209A1 (zh) * | 2021-11-10 | 2023-05-19 | 苏州瑞核医药科技有限公司 | 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用 |
| EP4436979A4 (en) * | 2021-11-26 | 2026-06-10 | Full Life Tech Uk Limited | Cleftable radioligands for targeting cell surface receptors and their uses |
| CA3244865A1 (en) * | 2022-03-04 | 2023-09-07 | Provincial Health Services Authority | RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
| CN115010629B (zh) * | 2022-06-07 | 2024-02-23 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用 |
| US20260083865A1 (en) * | 2022-09-07 | 2026-03-26 | 3B Pharmaceuticals Gmbh | Prostate specific membrane antigen (psma) ligands and use thereof |
| TW202410923A (zh) * | 2022-09-09 | 2024-03-16 | 大陸商同宜醫藥（蘇州）有限公司 | 放射性核種偶聯藥物及其藥物組成物和應用 |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| IL319722A (en) | 2022-09-23 | 2025-05-01 | Nuclidium Ag | High purity radionuclides and their diagnostic and medical uses |
| EP4667019A1 (en) * | 2023-02-16 | 2025-12-24 | Norroy Bioscience Co., Ltd. | Psma-targeted radiopharmaceutical, and synthesis and use thereof |
| EP4719498A1 (en) * | 2023-05-31 | 2026-04-08 | Full-Life Technologies UK Limited | Radioligands for targeting cell surface receptors and uses thereof |
| EP4719486A1 (en) * | 2023-05-31 | 2026-04-08 | Full-Life Technologies UK Limited | Conjugates and uses thereof |
| AU2024317528A1 (en) | 2023-07-31 | 2026-03-05 | Curium Us Llc | [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof |
| WO2025088147A1 (en) * | 2023-10-27 | 2025-05-01 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis |
| WO2025218879A1 (en) | 2024-04-15 | 2025-10-23 | Itm Technologies Munich Se | Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same |
| EP4763231A1 (en) | 2024-12-20 | 2026-06-24 | ITM Isotope Technologies Munich SE | Para-aminohippuric acid as a stabilizer in radiopharmaceutical compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| US9687572B2 (en) * | 2010-12-06 | 2017-06-27 | Molecular Insight Pharmaceuticals, Inc. | PSMA-targeted dendrimers |
| JP5843338B2 (ja) | 2011-08-05 | 2016-01-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 放射標識された前立腺特異的膜抗原阻害剤 |
| DK2766364T3 (da) | 2011-08-17 | 2024-09-30 | Merck & Cie | Folatkonjugater af albumin-bindende enheder |
| SMT202300035T1 (it) | 2013-03-15 | 2023-05-12 | Cancer Targeted Tech Llc | Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi |
| EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| AU2014336638C1 (en) | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| MX392700B (es) | 2016-08-10 | 2025-03-11 | Cancer Targeted Tech Llc | Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados. |
-
2018
- 2018-05-24 CA CA3060143A patent/CA3060143A1/en active Pending
- 2018-05-24 JP JP2019562312A patent/JP7340459B2/ja active Active
- 2018-05-24 US US16/616,744 patent/US11629201B2/en active Active
- 2018-05-24 WO PCT/EP2018/063734 patent/WO2018215627A1/en not_active Ceased
- 2018-05-24 KR KR1020197038065A patent/KR102843240B1/ko active Active
- 2018-05-24 CN CN201880034324.3A patent/CN110740757B/zh active Active
- 2018-05-24 EP EP18725856.1A patent/EP3630204B1/en active Active
- 2018-05-24 AU AU2018274184A patent/AU2018274184B2/en active Active
-
2019
- 2019-10-16 ZA ZA2019/06832A patent/ZA201906832B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018274184B2 (en) | 2024-06-13 |
| CA3060143A1 (en) | 2018-11-29 |
| KR20200009091A (ko) | 2020-01-29 |
| JP7340459B2 (ja) | 2023-09-07 |
| US11629201B2 (en) | 2023-04-18 |
| CN110740757B (zh) | 2023-04-04 |
| RU2019141963A (ru) | 2021-06-24 |
| WO2018215627A1 (en) | 2018-11-29 |
| EP3630204A1 (en) | 2020-04-08 |
| KR102843240B1 (ko) | 2025-08-05 |
| US20210009715A1 (en) | 2021-01-14 |
| EP3630204B1 (en) | 2026-07-01 |
| RU2019141963A3 (enExample) | 2021-09-22 |
| AU2018274184A1 (en) | 2019-11-07 |
| JP2020520902A (ja) | 2020-07-16 |
| CN110740757A (zh) | 2020-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906111B (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| GEP20217211B (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| PH12020500371A1 (en) | Spirocycle compounds and methods of making and using same | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| SA519410320B1 (ar) | مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل | |
| PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| WO2015120062A3 (en) | Therapeutic compounds and compositions | |
| JOP20200023A1 (ar) | مركبات حلقية لولبية وطرق تصنيعها واستخدامها | |
| HK1254231A1 (zh) | 米托-和厚朴酚化合物及其合成方法和用途 | |
| PT3573620T (pt) | Composições para o tratamento da hipertensão | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades, | |
| EA201691896A1 (ru) | Соединения и способы их применения | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. | |
| NZ751032A (en) | Methods for treating ovarian cancer | |
| EA202090107A2 (ru) | Композиции, содержащие бактериальные штаммы | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro |